HGEN News and Press, Humanigen Inc. From 10/15/19

BURLINGAME, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Humanigen, Inc., (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on the development of next generation CAR-T and other cell therapies, announced today that it is contemplating conducting a br...

NEW YORK , Oct. 14, 2019 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the October 10 th conference are now available for on-demand viewing at VirtualInvestorConferences.com. RE...

GM-CSF from the donor T cells initiates a cascade that drives lethal GvHD Without GM-CSF signaling, there was a significant reduction in acute GvHD Provide a logical rationale to administer lenzilumab (to neutralize GM-CSF) early after allogeneic transplant to prevent or treat high risk ...

BURLINGAME, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Humanigen, Inc., (HGEN) (“Humanigen”) a clinical stage biopharmaceutical company focused on the development of next generation cell and gene therapies using its proprietary granulocyte-macrophage colony stimulating factor...

Live Investor Conference & Webinar: Executives from Small and MicroCap companies present October 10th Live Investor Conference & Webinar: Executives from Small and MicroCap companies present October 10th Canada NewsWire NEW YORK, Oct. 4, 2019 Company executives wi...

Humanigen ( OTCQB:HGEN ) inks an agreement with the University of Zurich (UZH) securing exclusive global rights to technology used to prevent graft versus host disease (GvHD) via granulocyte macrophage-colony stimulating factor (GM-CSF) neutralization. More news on: Humanigen, Inc., Heal...

Expands Humanigen’s extensive intellectual property portfolio to include prevention of Graft-versus-Host Disease (GvHD) Strengthens Humanigen’s leadership position and platform in granulocyte macrophage-colony stimulating factor (GM-CSF) neutralization to include ...

Expands Humanigen’s intellectual property portfolio to include gene-edited CAR-T cells Builds and further strengthens Humanigen’s leadership position in GM-CSF neutralization GM-CSF neutralization has the potential to break the efficacy/toxicity linkage of C...

Expands Humanigen’s intellectual property portfolio to include gene-edited CAR-T cells Builds and further strengthens Humanigen’s leadership position in GM-CSF neutralization GM-CSF neutralization has the potential to break the efficacy/toxicity linkage of C...

BURLINGAME, Calif., June 03, 2019 (GLOBE NEWSWIRE) -- Humanigen, Inc., (HGEN) (“Humanigen”) a biopharmaceutical company focused on the development of its proprietary Humaneered ® monoclonal antibodies focused on chimeric antigen receptor T (CAR-T) cell therapy optimiza...